Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:06:46.541Z.
Calculation as of: 2026-10-06T17:06:46.541Z.
Quote observation: 2026-10-06T17:04:56.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Enliven Therapeutics, Inc.
Market Cap
$3.00B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.02B
Operating Cash Flow Yield
1.30%
TTM Avg
0.97%
3Y Avg
0.97%
5Y Avg
0.97%
Market Cap
$3.07B
Operating Cash Flow Yield
N/A
TTM Avg
9.93%
3Y Avg
9.93%
5Y Avg
9.93%
Market Cap
$3.09B
Operating Cash Flow Yield
N/A
TTM Avg
6.43%
3Y Avg
5.84%
5Y Avg
5.84%
Market Cap
$2.83B
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.81B
Operating Cash Flow Yield
5.19%
TTM Avg
4.84%
3Y Avg
2.97%
5Y Avg
2.97%
Market Cap
$3.19B
Operating Cash Flow Yield
2.50%
TTM Avg
2.45%
3Y Avg
2.45%
5Y Avg
1.16%
Market Cap
$2.79B
Operating Cash Flow Yield
2.33%
TTM Avg
3.24%
3Y Avg
1.81%
5Y Avg
1.81%
Market Cap
$2.71B
Operating Cash Flow Yield
N/A
TTM Avg
1.08%
3Y Avg
1.08%
5Y Avg
1.08%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.00B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.02B | 1.30% | 0.97% | 0.97% | 0.97% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.07B | N/A | 9.93% | 9.93% | 9.93% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.09B | N/A | 6.43% | 5.84% | 5.84% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.83B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | 5.19% | 4.84% | 2.97% | 2.97% |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | 2.50% | 2.45% | 2.45% | 1.16% |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 2.33% | 3.24% | 1.81% | 1.81% |
| Precigen, Inc. (PGEN)vs › | $2.71B | N/A | 1.08% | 1.08% | 1.08% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.32B | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
